Covid vax effectiveness declines after 6 months without boosters: Study

The study indicated that vaccines were 94 per cent effective at preventing hospitalisation 50-100 days after receiving the shot but fell to 80.4 per cent 200-250 days later

Coronavirus, Covid-19, testing, tests
IANS New York
2 min read Last Updated : Feb 26 2022 | 2:00 PM IST

The effectiveness of the Covid-19 vaccine may substantially decline after six months if booster shots are not taken, according to a new study published in The Lancet Respiratory Medicine.

The study indicated that vaccines were 94 per cent effective at preventing hospitalisation 50-100 days after receiving the shot but fell to 80.4 per cent 200-250 days later, with even more rapid declines after 250 days.

"This data helps us understand differences in waning protection by vaccine type and identify the key risk factors for severe breakthrough infections to help inform the targeting of potential vaccine booster programmes," said Amy Compton-Phillips, Providence chief clinical officer.

"Unlike most other studies, our data stretched beyond six months, where we found evidence of rapidly waning protection, especially for patients 80 or older," Compton-Phillips added.

In addition to examining the effectiveness of vaccines over time, the Providence study was also able to identify factors associated with reduced vaccine effectiveness.

Key risk factors for a severe "breakthrough" infection included advanced age (80+), comorbidities such as cancer, transplants, chronic kidney disease, hypertension, or heart failure, the amount of time that had elapsed since being vaccinated, and the type of vaccine one received.

For the latter factor, the study found that the Moderna vaccine offered the best overall protection over time, while the Pfizer-BioNTech vaccine offered initial protection equivalent to Moderna's but declined more rapidly over time.

Persons receiving the Janssen vaccine also had higher odds of experiencing a severe breakthrough infection compared to Moderna.

For the study, the research team examined data from nearly 50,000 hospital admissions between April and November of 2021.

--IANS

vc/shb/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineLancet reportResearch studyCommunicable diseaseshealth care

First Published: Feb 26 2022 | 2:00 PM IST

Next Story